::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

STUDY TO DETERMINE THE NEPHROTIC SYNDROME MANAGEMENT: ISKDC VERSUS APN

AUTHORS:

Dr Fatima Noor, Dr Zahra Hassan, Dr Mariam Mushtaq

ABSTRACT:

Aim: To compare the recurrence rate between ISKDC and APN protocol in the treatment of nephrotic syndrome. Study Design: A Randomized Control Trial. Place and Duration: In the Pediatric unit-II of mayo Hospital Lahore for one-year duration from June 2019 to June 2020. Methodology: Total 92 patients, 46 patients in each group, were selected according to non-probability purposive sampling including all nephrotic patients age 1 to 16 years keeping in mind the confounders, then allocating them into group 1 receiving ISKDC and group 2 (APN) randomly and following them for a year. First relapse was the end point of study. Results In group 1, 4% of patients relapsed in the first month, 13% after three, 35% after six months, and 72% after one year. In group 2, none of the patients relapsed in the first month, 2% after 3 months, 15% after six months, and 30% after one year. The P value was 0.026. Longer duration of steroid use was important in reducing the risk of relapse at the end of the study (relative risk 0.72) (95% CI 0.60-0.90). Conclusion: APN is superior to ISKDC in preventing nephrotic syndrome recurrence. Key words: nephrotic, APN, ISKDC, relapses.